Leptomeningeal carcinomatosis. Presenting features and prognostic factors

M. Balm and J. Hammack
Department of Neurology, Mayo Clinic, Rochester, Minn, USA.

OBJECTIVE: To determine factors that are predictive of survival among patients with leptomeningeal carcinomatosis. BACKGROUND: Studies of potential prognostic factors in leptomeningeal carcinomatosis have produced conflicting results. Reasons for the discrepancies may be methodological differences in case ascertainment, treatment protocols, and limitations due to the size of the study group. DESIGN AND METHODS: We reviewed the medical records of 126 patients with cytologically confirmed leptomeningeal carcinomatosis seen at the Mayo Clinic in Rochester, Minn, from 1983 to 1994. Clinical, radiographic, and cerebrospinal fluid (CSF) parameters at the time of presentation are summarized. Treatment response, complications, and cause of death are also discussed. Using the forward stepwise Cox model, independent predictors of survival were identified. RESULTS: Independent negative predictors of survival include elevated CSF protein (P < .001) and clinical involvement of the cerebral leptomeninges (P = .05). Independent positive predictors of survival were longer duration of neurological symptoms at the time of presentation (P < .005), treatment with intrathecal or intraventricular (intra-CSF) chemotherapy (P = .01), and female sex (P = .02). Other variables, including age, primary tumor type, and extent of systemic disease, were not predictive. CONCLUSIONS: We conclude that female sex, longer duration of neurological symptoms, absence of cerebral leptomeningeal clinical involvement, and absence of elevated CSF protein independently predict better survival. Patients treated with intra-CSF chemotherapy also survived longer.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neoplastic Meningitis
Chamberlain
The Oncologist 2008;13:967-977.
ABSTRACT | FULL TEXT  

A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
Groves et al.
Neuro Oncol 2008;10:208-215.
ABSTRACT | FULL TEXT  

Leptomeningeal carcinomatosis: cerebrospinal fluid findings.
Habek et al.
Arch Neurol 2006;63:910-910.
FULL TEXT  

Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases
Brandsma et al.
Neurology 2006;66:243-246.
ABSTRACT | FULL TEXT  

Neoplastic Meningitis
Chamberlain
JCO 2005;23:3605-3613.
ABSTRACT | FULL TEXT  

MR Imaging of Leptomeningeal Metastases: Comparison of Three Sequences
Singh et al.
Am. J. Neuroradiol. 2002;23:817-821.
ABSTRACT | FULL TEXT  

Intracranial Leptomeningeal Metastases: Comparison of Depiction at FLAIR and Contrast-enhanced MR Imaging
Singh et al.
Radiology 2000;217:50-53.
ABSTRACT | FULL TEXT  

A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumors
Glantz et al.
Clin. Cancer Res. 1999;5:3394-3402.
ABSTRACT | FULL TEXT  

Presenting features and value of diagnostic procedures in leptomeningeal metastases
van Oostenbrugge and Twijnstra
Neurology 1999;53:382-382.
ABSTRACT | FULL TEXT  

Carcinoma Meningitis Secondary to Non-Small Cell Lung Cancer: Combined Modality Therapy
Chamberlain and Kormanik
Arch Neurol 1998;55:506-512.
ABSTRACT | FULL TEXT